Literature DB >> 10851250

Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population.

X P Zhou1, W M Smith, O Gimm, E Mueller, X Gao, P Sarraf, T W Prior, C Plass, A von Deimling, P M Black, A J Yates, C Eng.   

Abstract

PPARgamma, the gamma isoform of a family of peroxisome proliferator activated receptors, plays a key role in adipocyte differentiation. Recently, its broad expression in multiple tissues and several epithelial cancers has been shown. Further, somatic loss of function mutations in PPARgamma have been found in primary colorectal carcinomas. We sought to determine if somatic high penetrance mutations in this gene might also play a role in glioblastoma multiforme (GBM). We also examined this gene to determine if common low penetrance polymorphic alleles might lend low level susceptibility to GBM in the general population. No somatic high penetrance mutations were detected in 96 sporadic GBMs. However, polymorphic alleles at codons 12 and 449 were significantly over-represented among the 27 unrelated American patients with sporadic GBM compared to 80 race matched controls. While nine (33%) were heterozygous for the P12A variant, c.34C/G (cytosine to guanine change at nucleotide 34), 12 (15%) controls were heterozygous for P12A (p<0.05). Similarly, 13 of 26 (50%) glioblastoma patients compared to 10 of 80 (12%) normal controls were found to have the heterozygous H449H polymorphism (p<0.001). The over-representation of H449H in glioblastoma patients was confirmed with a second validation set of American patients. When both American series were combined, polymorphic H449H was over-represented among cases versus controls (p<0.001) and there was a similar trend (p=0.07) for P12A. The precise mechanism for this association is unknown but these PPARgamma polymorphisms may be acting in a low penetrance predisposing manner. However, these associations were not found in a German population, possibly arguing that if these variants are in linkage disequilibrium with a third locus, then this effect is relatively new, after the settlement of the American colonies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851250      PMCID: PMC1734615          DOI: 10.1136/jmg.37.6.410

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  23 in total

1.  Linkage disequilibrium mapping in isolated populations: the example of Finland revisited.

Authors:  A de la Chapelle; F A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 2.  Etiology of brain tumors in adults.

Authors:  P D Inskip; M S Linet; E F Heineman
Journal:  Epidemiol Rev       Date:  1995       Impact factor: 6.222

3.  Nutritional factors in the etiology of brain tumors: potential role of nitrosamines, fat, and cholesterol.

Authors:  S Kaplan; I Novikov; B Modan
Journal:  Am J Epidemiol       Date:  1997-11-15       Impact factor: 4.897

4.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.

Authors:  D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons
Journal:  Nat Genet       Date:  1997-05       Impact factor: 38.330

5.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

Authors:  E Saez; P Tontonoz; M C Nelson; J G Alvarez; U T Ming; S M Baird; V A Thomazy; R M Evans
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

6.  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.

Authors:  A Elbrecht; Y Chen; C A Cullinan; N Hayes; M d Leibowitz; D E Moller; J Berger
Journal:  Biochem Biophys Res Commun       Date:  1996-07-16       Impact factor: 3.575

7.  Deletion of genes on chromosome 1 in endocrine neoplasia.

Authors:  C G Mathew; B A Smith; K Thorpe; Z Wong; N J Royle; A J Jeffreys; B A Ponder
Journal:  Nature       Date:  1987 Aug 6-12       Impact factor: 49.962

8.  A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

Authors:  S A Kliewer; J M Lenhard; T M Willson; I Patel; D C Morris; J M Lehmann
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

9.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

Authors:  B M Forman; P Tontonoz; J Chen; R P Brun; B M Spiegelman; R M Evans
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

10.  Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor.

Authors:  P Tontonoz; E Hu; B M Spiegelman
Journal:  Cell       Date:  1994-12-30       Impact factor: 41.582

View more
  12 in total

1.  Peroxisome proliferator-activated receptor-gamma 34C>G polymorphism and colorectal cancer risk: a meta-analysis.

Authors:  Yong-Liang Lu; Gai-Ling Li; Hui-Lian Huang; Jing Zhong; Li-Cheng Dai
Journal:  World J Gastroenterol       Date:  2010-05-07       Impact factor: 5.742

2.  Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer.

Authors:  George Theodoropoulos; Ioannis Papaconstantinou; Evangelos Felekouras; Nikolaos Nikiteas; Petros Karakitsos; Dimitris Panoussopoulos; Andreas Ch Lazaris; Efstratios Patsouris; John Bramis; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma 'on/off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression.

Authors:  Panagiotis A Konstantinopoulos; Gerasimos P Vandoros; Georgia Sotiropoulou-Bonikou; Athina Kominea; Athanasios G Papavassiliou
Journal:  Int J Colorectal Dis       Date:  2006-02-25       Impact factor: 2.571

4.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Authors:  E Mueller; M Smith; P Sarraf; T Kroll; A Aiyer; D S Kaufman; W Oh; G Demetri; W D Figg; X P Zhou; C Eng; B M Spiegelman; P W Kantoff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

5.  APC-dependent suppression of colon carcinogenesis by PPARgamma.

Authors:  Geoffrey D Girnun; Wendy M Smith; Stavit Drori; Pasha Sarraf; Elisabetta Mueller; Charis Eng; Prashant Nambiar; Daniel W Rosenberg; Roderick T Bronson; Winfried Edelmann; Raju Kucherlapati; Frank J Gonzalez; Bruce M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

6.  Peroxisome proliferator-activated receptor gamma (PPARG) rs1801282 C>G polymorphism is associated with cancer susceptibility in asians: an updated meta-analysis.

Authors:  Yafeng Wang; Yu Chen; Heping Jiang; Weifeng Tang; Mingqiang Kang; Tianyun Liu; Zengqing Guo; Zhiqiang Ma
Journal:  Int J Clin Exp Med       Date:  2015-08-15

7.  Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors.

Authors:  Lars Tatenhorst; Eric Hahnen; Michael T Heneka
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

Review 8.  Biological Rationale for the Use of PPARγ Agonists in Glioblastoma.

Authors:  Hayley Patricia Ellis; Kathreena Mary Kurian
Journal:  Front Oncol       Date:  2014-03-14       Impact factor: 6.244

9.  PPARG c.1347C>T polymorphism is associated with cancer susceptibility: from a case-control study to a meta-analysis.

Authors:  Hao Ding; Yuanmei Chen; Hao Qiu; Chao Liu; Yafeng Wang; Mingqiang Kang; Weifeng Tang
Journal:  Oncotarget       Date:  2017-09-15

Review 10.  Metabolic Reprogramming in Glioma.

Authors:  Marie Strickland; Elizabeth A Stoll
Journal:  Front Cell Dev Biol       Date:  2017-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.